New hope for tough lymphoma: Triple-Drug attack
NCT ID NCT07598578
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) in 30 adults with peripheral T-cell lymphoma that has not responded to or has returned after prior treatment. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants will receive the drugs intravenously or orally over several cycles, with regular monitoring for response and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Soochow University Suzhou
RECRUITINGSuzhou, 215000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••